Patients with Alpha 1 Antitrypsin Deficiency (AATD), which causes early onset emphysema, will have to wait at least a year for any decision on funding for TGA-listed augmentation treatments, the government says. A patient petition to fast track funding for alpha I proteinase inhibitor products such as Zemaira and Prolastin-C has a received a response from ...
Funding plea for early-onset emphysema therapies
By Michael Woodhead
22 Feb 2018